BOTHELL, Wash., June 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for PYY3-36 (PYY) nasal spray, the company’s lead investigational product candidate for treatment of obesity. The filing of the IND precedes the initiation of clinical studies in the United States.
